J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Shareholders might have noticed that J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) filed its quarterly result this time last week. The early response was not positive, with shares down 6.1% to ₹1,841 in the past week. Results were roughly in line with estimates, with revenues of ₹10b and statutory earnings per share of ₹11.00. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

See our latest analysis for J. B. Chemicals & Pharmaceuticals

Taking into account the latest results, the current consensus from J. B. Chemicals & Pharmaceuticals' 14 analysts is for revenues of ₹40.3b in 2025. This would reflect a meaningful 8.5% increase on its revenue over the past 12 months. Statutory earnings per share are predicted to climb 15% to ₹45.19. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹40.5b and earnings per share (EPS) of ₹45.84 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

The analysts reconfirmed their price target of ₹2,150, showing that the business is executing well and in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on J. B. Chemicals & Pharmaceuticals, with the most bullish analyst valuing it at ₹2,329 and the most bearish at ₹1,651 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 18% growth on an annualised basis. That is in line with its 17% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 11% annually. So although J. B. Chemicals & Pharmaceuticals is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple J. B. Chemicals & Pharmaceuticals analysts - going out to 2027, and you can see them free on our platform here.

However, before you get too enthused, we've discovered 2 warning signs for J. B. Chemicals & Pharmaceuticals that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.